Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial.

Autor:	Banovic M; Belgrade Medical School, University of Belgrade, Serbia.; Cardiology Department, University Clinical Center of Serbia, Belgrade, Serbia., Putnik S; Belgrade Medical School, University of Belgrade, Serbia.; Cardiac-Surgery Department, University Clinical Center of Serbia, Belgrade, Serbia., Da Costa BR; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom., Penicka M; Cardiovascular Center, OLV Hospital, Aalst, Belgium., Deja MA; Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland., Kotrc M; Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Kockova R; Charles University, Faculty of medicine Hradec Králové, Czech Republic., Glaveckaite S; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Gasparovic H; Department of Cardiac Surgery, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia., Pavlovic N; University Hospital Dubrava, Zagreb, Croatia., Velicki L; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Institute of Cardiovascular Diseases Vojvodina, Sremska Kamenica, Serbia., Salizzoni S; Division of Cardiacsurgery, Cardiovascular and Thoracic Department, University of Turin, Italy., Wojakowski W; Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland., Van Camp G; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom., Gradinac S; Sabah Al Ahmad Cardiac Center, Amiri Hospital, Kuwait., Laufer M; Mach Ventures, Menlo Park, California, USA., Tomovic S; Belgrade Medical School, University of Belgrade, Serbia., Busic I; Belgrade Medical School, University of Belgrade, Serbia., Bojanic M; Anesteziology Department, 'Institute Banjica'; Serbia., Ristic A; Belgrade Medical School, University of Belgrade, Serbia.; Cardiology Department, University Clinical Center of Serbia, Belgrade, Serbia., Klasnja A; University Clinical Center 'Bezanijska Kosa', Serbia., Matkovic M; Belgrade Medical School, University of Belgrade, Serbia.; Cardiac-Surgery Department, University Clinical Center of Serbia, Belgrade, Serbia., Boskovic N; Cardiology Department, University Clinical Center of Serbia, Belgrade, Serbia., Zivic K; Cardiology Department, University Clinical Center of Serbia, Belgrade, Serbia., Jovanovic M; General Hospital 'Pozarevac', Serbia., Nikolic SD; CorDynamix, Redwood City, CA, USA., Iung B; Cardiology Department, Bichat Hospital APHP and Universite Paris-Cité, France., Bartunek J; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Jazyk:	angličtina
Zdroj:	European heart journal [Eur Heart J] 2024 Sep 01. Date of Electronic Publication: 2024 Sep 01.
DOI:	10.1093/eurheartj/ehae585
Abstrakt:	Background and Aims: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, clinical trials.gov). Methods: The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke or unplanned hospitalization for heart failure (HF), as compared to conservative treatment strategy. Results: A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either early AVR group (n=78) or conservative treatment group (n=79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group (hazard ratio [HR] early surgery vs. conservative treatment 0.42; 95% confidence interval [CI] 0.24-0.73, p=0.002). The Kaplan-Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23-0.85, p=0.012 for all-cause death, and HR 0.21; 95% CI 0.06-0.73, p=0.007 for HF hospitalizations). Conclusions: The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting. Trial Registration Number: NCT02436655 (ClinicalTrials.gov). (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu